Saturday 17 October 2026
Export LGND’s income statement to Excel — free account
Ligand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024. In the quarter to June 2026, revenue grew 33.7%, EPS grew 868.0% and free cash flow grew 35.5%, each against the same quarter a year earlier.
295.54
2.96
−0.99%
Follow LGND
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
30.01 | 0.00 | 23.79 | 0.00 | 27.85 | 0.00 | 2.13 | 12.54 | 144.13 | 0.00 |
Piotroski F-Score |
6 | 5 | 6 | 4 | 7 | 5 | 5 | 7 | 8 | 5 |
P/S ratio |
13.64 | 11.73 | 9.53 | 5.68 | 6.63 | 6.14 | 10.27 | 7.12 | 12.89 | 12.22 |
Altman Z-Score |
5.45 | 11.78 | 10.04 | 5.45 | 3.34 | 1.89 | 4.14 | 2.66 | 3.68 | 2.33 |
P/FCF ratio |
60.02 | 21.84 | 0.00 | 9.96 | 23.24 | 20.56 | 0.00 | 9.42 | 19.20 | 32.34 |
Altman Z″-Score (non-manufacturers) |
6.75 | 11.45 | 12.55 | 7.17 | 5.61 | 4.19 | 10.46 | 5.22 | 0.26 | (1.17) |
Beneish M-Score |
(4.02) | (3.22) | (1.93) | (3.98) | (1.79) | (1.56) | (0.57) | (2.08) | (2.41) | (1.78) |
P/Operating CF |
79.63 | 68.83 | 155.09 | 20.83 | 57.97 | 1,869.86 | (168.39) | 54.99 | 58.09 | 71.13 |
P/B ratio |
3.59 | 2.36 | 1.78 | 1.86 | 1.95 | 1.42 | 1.61 | 3.19 | 4.55 | 3.90 |
Price to Tangible BV |
5.30 | 4.27 | 4.20 | 8.00 | 4.88 | 0.00 | 2.80 | 8.03 | 27.68 | 34.54 |
EV/Sales |
12.77 | 10.63 | 8.86 | 5.04 | 6.56 | 6.38 | 6.70 | 6.58 | 13.19 | 13.15 |
EV/EBITDA |
48.15 | 150.69 | 24.55 | 17.87 | 9.23 | 11.59 | 0.93 | 7.62 | 20.37 | 21.57 |
EV/Operating CF |
69.35 | 18.30 | 23.46 | 7.17 | 20.10 | 19.11 | (27.47) | 8.52 | 21.01 | 23.60 |
EV/FCF |
56.19 | 19.80 | (301.84) | 8.84 | 22.98 | 21.36 | (22.97) | 8.70 | 19.64 | 34.80 |
Quick Ratio |
21.83 | 8.32 | 12.49 | 2.50 | 10.39 | 4.70 | 65.38 | 10.09 | 0.95 | 0.69 |
Current Ratio |
22.23 | 8.93 | 14.15 | 2.67 | 11.15 | 5.00 | 66.09 | 10.58 | 0.99 | 0.72 |
Net Debt/EBITDA |
(4.36) | (22.58) | (3.59) | (2.26) | (0.11) | 0.43 | (0.49) | (0.63) | 0.46 | 1.53 |
Debt/Assets |
28.59% | 0.00% | 0.00% | 11.37% | 24.79% | 33.05% | 42.81% | 50.47% | 36.27% | 40.31% |
Debt/Equity |
0.44 | 0.00 | 0.00 | 0.15 | 0.39 | 0.63 | 0.83 | 1.13 | 0.61 | 0.71 |
Asset Turnover |
0.21 | 0.19 | 0.17 | 0.19 | 0.18 | 0.11 | 0.09 | 0.26 | 0.22 | 0.20 |
Operating CF/Net income |
0.40 | (24.07) | 0.95 | (4.13) | 1.38 | (18.29) | (0.05) | 1.35 | 7.05 | (37.12) |
Capex/Depreciation |
(0.03) | (0.35) | (1.51) | (0.34) | (0.12) | (0.06) | (0.04) | (0.20) | 0.21 | (0.87) |
Interest Coverage |
8.70 | (7.44) | 18.20 | 1.69 | 5.29 | 1.37 | 22.58 | 3.39 | 5.06 | 3.42 |
| 13.47% | (0.53%) | 8.03% | (4.70%) | 7.47% | (0.40%) | 94.76% | 29.84% | 3.39% | (0.57%) | |
| 9.95% | (0.47%) | 6.73% | (3.24%) | 4.30% | (0.21%) | 45.67% | 14.84% | 1.97% | (0.30%) | |
ROIC |
3.62% | (2.50%) | 1.41% | 0.40% | 8.10% | 3.13% | 149.54% | 24.17% | 9.64% | 6.20% |
Return on Tangible Assets |
15.66% | (1.30%) | 22.08% | (18.82%) | 13.10% | (0.72%) | 56.50% | 18.06% | 530.91% | 2.63% |
Average Days of Receivables |
83.12 | 92.70 | 109.27 | 65.17 | 138.49 | 131.81 | 126.69 | 81.28 | 66.21 | 49.24 |
Research and Development Expense of Revenue |
30.28% | 12.82% | 18.69% | 18.39% | 13.29% | 24.76% | 46.48% | 11.08% | 19.06% | 19.47% |
Selling, General and Administrative Expense of Revenue |
34.48% | 47.06% | 40.20% | 35.70% | 19.37% | 36.69% | 34.82% | 15.01% | 20.31% | 25.38% |
Intangible Assets out of Total Assets |
0.21 | 0.39 | 0.51 | 0.60 | 0.38 | 0.58 | 0.22 | 0.27 | 0.50 | 0.50 |
Share Based Compensation of Revenue |
17.48% | 24.58% | 19.60% | 30.72% | 16.06% | 18.79% | 20.38% | 8.29% | 17.66% | 17.34% |
Graham Net Nets |
0.08 | 0.11 | 0.12 | 0.09 | (0.01) | (0.15) | 0.32 | 0.10 | (0.02) | (0.07) |
Graham Number |
86.35 | 0.00 | 52.64 | 0.00 | 62.00 | 0.00 | 166.79 | 63.45 | 16.02 | 0.00 |
Earnings Yield |
3.33% | (0.05%) | 4.20% | (3.00%) | 3.59% | (0.23%) | 47.05% | 7.97% | 0.69% | (0.09%) |
Free Cash Flow Yield |
1.67% | 4.58% | (0.31%) | 10.04% | 4.30% | 4.86% | (2.84%) | 10.61% | 5.21% | 3.09% |
Revenue per Share |
13.86 | 9.14 | 7.59 | 11.63 | 14.52 | 10.11 | 6.33 | 11.88 | 6.71 | 5.23 |
Operating CF per Share |
2.55 | 5.31 | 2.87 | 8.17 | 4.74 | 3.37 | (1.54) | 9.17 | 4.21 | 2.92 |
Capex per Share |
(0.05) | (0.67) | (3.09) | (1.06) | (0.50) | (0.19) | (0.13) | (0.51) | 0.23 | (0.94) |
Free Cash Flow per Share |
2.50 | 4.64 | (0.22) | 7.12 | 4.24 | 3.18 | (1.68) | 8.66 | 4.44 | 1.98 |
Cash per Share |
39.11 | 14.55 | 9.85 | 12.56 | 20.51 | 25.41 | 56.32 | 36.57 | 9.59 | 6.77 |
Shareholders Equity per Share |
52.60 | 45.40 | 40.52 | 35.42 | 49.38 | 43.84 | 40.39 | 26.51 | 19.01 | 16.38 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
52.60 | 45.40 | 40.52 | 35.42 | 49.38 | 43.84 | 40.39 | 26.51 | 19.01 | 16.38 |
Free Cash Flow |
48.31 | 84.84 | (3.85) | 120.02 | 70.53 | 51.49 | (31.89) | 183.17 | 93.47 | 41.19 |
Working Capital |
794.82 | 294.45 | 220.65 | 164.79 | 423.09 | 400.45 | 1,106.64 | 788.29 | (1.85) | (64.08) |
Capital Expenditures |
(1.05) | (12.21) | (53.43) | (17.83) | (8.27) | (3.10) | (2.55) | (10.89) | 4.90 | (19.54) |
Net Current Asset Value |
288.85 | 220.22 | 151.13 | 98.42 | (11.68) | (152.20) | 395.96 | 170.65 | (34.21) | (97.24) |
EV/EBIT |
83.48 | 0.00 | 97.41 | 325.52 | 15.25 | 27.82 | 1.00 | 10.10 | 27.33 | 32.66 |
Capex to Sales |
0.00 | 0.07 | 0.41 | 0.09 | 0.03 | 0.02 | 0.02 | 0.04 | (0.03) | 0.18 |
Price to Operating Income |
89.17 | 0.00 | 104.74 | 366.74 | 15.43 | 26.78 | 1.53 | 10.94 | 26.72 | 30.35 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 2.27 | 2.27 | 4.19 | 5.14 | 3.64 | 8.83 | 9.91 | 5.52 | 12.40 |
Cash ROIC |
2.18% | 7.74% | (0.44%) | 13.39% | 4.75% | 3.28% | (1.29%) | 9.29% | 11.06% | 5.68% |
Accounts Receivable Turnover |
5.18 | 4.09 | 3.53 | 3.10 | 3.21 | 3.24 | 2.46 | 6.16 | 7.00 | 10.44 |
Accounts Payable Turnover |
3.44 | 2.89 | 2.72 | 7.71 | 10.20 | 9.81 | 3.44 | 1.97 | 2.15 | 1.63 |
Inventory Turnover |
1.25 | 0.58 | 0.56 | 2.60 | 2.31 | 1.80 | 1.57 | 1.10 | 1.70 | 3.13 |
Average Days of Payables |
81.23 | 172.48 | 84.27 | 36.67 | 49.33 | 45.40 | 77.84 | 240.93 | 153.66 | 179.13 |
Days of Inventory on Hand |
228.95 | 465.20 | 832.26 | 91.85 | 160.42 | 317.82 | 234.69 | 410.33 | 297.46 | 125.99 |
Average Receivables |
51.75 | 40.88 | 37.18 | 63.34 | 75.36 | 50.41 | 48.87 | 40.79 | 20.15 | 10.44 |
Average Payables |
4.24 | 3.83 | 3.87 | 6.86 | 6.09 | 3.10 | 3.30 | 3.22 | 2.50 | 3.41 |
Average Inventory |
11.62 | 19.04 | 18.63 | 20.31 | 26.91 | 16.89 | 7.21 | 5.75 | 3.15 | 1.78 |
Average Assets |
1,251.21 | 864.50 | 774.94 | 1,030.13 | 1,329.94 | 1,428.60 | 1,377.86 | 965.91 | 636.30 | 552.32 |
Average Common Equity |
923.83 | 765.68 | 649.20 | 709.32 | 765.34 | 738.38 | 664.07 | 480.35 | 370.54 | 289.29 |
Columns are period end dates